SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- October 06, 2006 -- Theravance, Inc. (NASDAQ: THRX) today announced that it will host an investor conference call at 8:00 a.m. Eastern Daylight Time on October 11, 2006 to discuss the results from ATLAS 1 and ATLAS 2, the telavancin Phase 3 program for the treatment of complicated skin and skin structure infections. The conference call will follow a presentation given the previous day at the Third International Symposium on Resistant Gram-Positive Infections.
